Additional programme:
BEAM Alliance meet-up (for members only)

Additional programme:
Expert campus | Top 10 mistakes in antibacterial development

Jointly organised by Novo REPAIR Impact Fund, CARB-X, GARDP and Wellcome Trust

Moderator:

• Ursula Theuretzbacher – Founder, CEFAIA

Speakers:

• Peter Warn – SVP, Anti-infective Discovery, Evotec
• Richard Knight – Director & Co–founder, ApconiX
• Aleksander Danilovski – CSO & Senior Vice President Global R&D and Regulatory Affairs, Xelia

Opening Session | Infectious diseases in the global spotlight: Why COVID-19 has an impact on AMR

Moderator: 

• Deborah A O’Neil – CEO, NovaBiotics Ltd & Board Member, BEAM Alliance

Speakers:

• Manica Balasegaram – Executive Director, GARDP
• Rafael Cantón – Head of the Clinical Microbiology Department, University Hospital Ramón y Cajal Madrid
• Sergio Carmona – Chief Access Officer, FIND

Further reading tips:

• Viewpoint: COVID-19 and why tackling the silent crisis of drug-resistant infections matters more than ever – by Manica Balasegaram 
• GARDP in the AMR Stakeholder Guide

Diagnostics | Why diagnostics are a gamechanger to control a pandemic and what this means for combatting AMR

Moderator and speaker:

• Sergio Carmona, Chief Access Officer, FIND

Speakers:

• Rosanna Peeling, Professor and Chair, Diagnostics Research & Director, International Diagnostics Centre, London School of Hygiene & Tropical Medicine
• Claudia Denkinger, Head of Division of Tropical Medicine, University Hospital Heidelberg
• Stefanie Deinhardt-Emmer, a clinical expert from University Clinic of Jena, Germany
• Joe Fitchett, Medical Director, Mologic

Further reading tips:

• The Lancet, 1 August, Rosanna Peeling et al: Diagnostics in the response to antimicrobial resistance 
• Overview of Antimicrobial Resistance Programme, FIND
• News release, 26 June, LSHTM: TB cases and deaths predicted to spike due to COVID-19 
• News release, 3 June, Mologic: Mologic CE Marks professional-use rapid diagnostic test for COVID-19 and begins manufacture 
• Infectognostics Research Campus Jena in the AMR Stakeholder Guide

One Health | Why it is more important than ever to think cross-sectoral

Moderator and Speaker:

• Ghada Zoubiane – Head of Partnerships and Stakeholder Engagement, ICARS

Speakers:

• Viviana Muñoz-Tellez – Coordinator, Development, Innovation and Intellectual Property Programme (DIIP), South-Centre
• Mark Holmes, Professor in Microbial Genomics & Veterinary Science, University of Cambridge
• Elmar Nimmesgern – Secretariat Lead, Global AMR R&D Hub
• Timo Minssen – Founder and Managing Director, Center for Advanced Studies in Biomedical Innovation Law (CeBIL)

Further reading tips:

• News release, 30 July, Global AMR R&D Hub: Announcing Launch of Animal Health AMR R&D Data – One Step closer to a One Health approach 
• Learn how your country can benefit from a partnership with ICARS
• Global antimicrobial resistance at Global Strategy Lab

Expert campus | How to accelerate AMR drug discovery & development

Moderation:

• Isabelle Bekeredjian-Ding – Head of Department, Paul-Ehrlich Institut

Speakers:

• Claus Stie Kallesøe – CEO & Co-founder, grit42
• Dirk Bumann – Professor for Infection Biology, The Center for Molecular Life Sciences, University of Basel
• Dave Madge – Vice President, Research Service Division, WuXi AppTec
• Cuong Vuong, Director Bacteriology, AiCuris

Further reading tips:

• Overview of Swiss research network NCCR AntiResist
• European Biotechnology Magazine, 18 August: Aicuris to launch AiCubator to fight AMR 
• By IMI AMR Accelerator & COMBINE project: Call for preclinical and clinical data sets from the study of prevention or treatment of bacterial infections 
• Explore these AMR Stakeholder Guide profiles: grit42, University of Basel, WuXi AppTec, AiCuris

ENABLE: A public-private partnership for antibiotic development

Speakers:

• Anders Karlén – ENABLE Coordinator, Uppsala University
• Jürgen Brem – Project Leader OU-ENABLE, Oxford University
• Francois Moreau – Scientific Director, Mutabilis
• Sven Hobbie – CEO & Co-founder, Juvabis

Further reading tips:

• Overview of ENABLE outcomes: What we have achieved
• Juvabis in the AMR Stakeholder Guide

Business models | The AMR company of the future – Which route to success

Sponsored by:

Moderator: 

• Erin Duffy – Chief of Research & Development, CARB-X

Speakers:

• Jonathan Butcher – Head of Business Development, BioVersys AG
• Cherif Bousselham – Senior Vice President, Head of Sales, EMEA, Accelerate Diagnostics Inc.
• Jean-Pierre Paccaud – Director of Business Development and Corporate Strategy, GARDP
• Kenneth Bradley – Global Head, Infectious Disease Discovery, Roche

Further reading tips:

• Read the latest funding news by CARB-X
• Explore these AMR Stakeholder Guide profiles: CARB-X, BioVersys AG, GARDP

Business models in AMR | How to develop strategic decisions in a challenging and global AMR market

Sponsored by:

Moderator: 

• Gökhan Batur – CEO, Polyphor Ltd

Speakers:

• Peter Beyer – Senior Advisor Department of Essential Medicines & Health Products, WHO
• Erin Duffy – Chief of Research & Development, CARB-X
• Holger Zimmermann – CEO, AiCuris

Further reading tips:

• ACS Infect. Dis. 2020, 12 June: By Peter Beyer & Sarah Paulin, WHO: The Antibacterial Research and Development Pipeline Needs Urgent Solutions
• Explore these AMR Stakeholder Guide profiles: Polyphor Ltd, CARB-X, AiCuris

AMR pull incentives | Will COVID-19 speed up or slow down implementation?

Moderator:

• Kathy Talkington, Director Health Programs, Pew Charitable Trust

Speakers:

• Suzanne Edwards – Programme Officer/Economist, Global AMR R&D Hub
• Kevin Outterson – Professor of Law & Executive Director, CARB-X
• Colm Leonard – Clinical Advisor/Consultant, NICE
• Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta

Further reading tips:

• Pew Trust: Take Action: Antibiotic resistance is a looming threat. Urge Your Senators to act
• Nature Magazine, 11 August: Pharmaceutical firms commit US$1 billion to antibiotic development 
• Stat News, 12th August, by Kevin Outterson: We need new antimicrobials to prevent the next infectious disease crisis 
• ACS Infect. Dis. 2020: Viewpoint, 12 June: By Wes Kim, The Pew Charitable Trust: On the Road to Discovering Urgently Needed Antibiotics: So Close Yet So Far Away 
• Explore these AMR Stakeholder Guide profiles: Global AMR R&D Hub, CARB-X

Diagnostics | Novel solutions to solve the reimbursement challenge

Moderator:

• Till Bachmann – Deputy Head of Infection Medicine and Personal chair of Molecular Diagnostics and Infection, University of Edinburgh

Speakers:

• Colm Leonard – Clinical Advisor/Consultant, NICE
• Philippe Cleuziat – Innovation Program Senior Director, bioMérieux, VALUE-Dx
• Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta
• Cecilia Ferreyra, Head of AMR Programme, FIND

Further reading tips:

• Overview of Value-Dx project
• More info about the free technical workshops and support sessions provided by Longitude Prize SPRINT Programme, launched July 2020
• FIND in the AMR Stakeholder Guide

Expert Campus | Diagnostics in clinical trial settings

Supported by:

Moderator:

• Daniel Berman – Lead of the Global Health Team, Longitude Prize / Nesta

Speakers:

• Kwangmin Son – Co-founder & CEO, Phast Corp.
• Michael Lobritz – Translational Project Leader, Roche
• Laurenz Kellenberger, CSO, Basilea

Further reading tips:

• Learn more about diagnostics company PHAST Corp.: https://phastdiagnostics.com & https://longitudeprize.org/teams/phast
• By CARB-X & Longitude Prize; 16 June: CARB-X AWARDS $3.2M TO LONGITUDE PRIZE CONTENDER, MODULE INNOVATIONS
• By Longitude Prize, 21 May: The long read: We must do better for UTI patients

Expert campus | Focus on tuberculosis

Supported by:

Moderation & Introduction:

• Santiago Ramón-García, Research & Development Agency of Aragon (ARAID) Foundation & Mycobacterial Genetics Group, Dept. of Microbiology, University of Zaragoza
• Ruben Hartkoorn – Institut Pasteur de Lille, INSERM

Speakers:

• Michel Pieren – Project Manager, BioVersys AG, CH
• Florian Kloss – Head, Hans Knöll Institute (HKI), GER
•  Michael Hoelscher – Network Coordinator, Ludwig-Maximilians-University Munich (LMU), GER

Further reading tips:

• Development of novel treatments to treat TB is in the focus of the IMI AMR Accelerator > Please find here more information about the ongoing projects: ERA4TB, TRIC-TB 
• Updated WHO information on TB & Covid-19, 12 May
  Article by ERA4TB & Stop TB Partnership, 20 May: The potential impact of the Covid-19 response on tuberculosis in high-burden countries: a modelling analysis 
• Harvard Medical School, 5 August: New generation of drugs show early efficacy against drug-resistant TB 
• Press release by LMU Munich & Leibniz HKI, 19 Nov 2019: New drug substance BTZ-043 is being tested on patients for the first time ​ 
• BioVersys AG in the AMR Stakeholder Guide

Expert campus | Diagnostics in Drug-resistant TB

Moderation: 

• Anita Suresh – Head of Sequencing, FIND

Speakers:

• Courtney Maus – Scientific Director Life Sciences, BD
• Sebastian Dümcke – CEO, Clemedi AG
• Dessislava Tarlton, Programme Management Officer, molecular diagnostics and cervical cancer, Unitaid

Further reading tips:

• Overview of tuberculosis programme at FIND
• From the CEO of FIND, Catharina Boehme, 24 March: COVID-19: a message of solidarity on World TB Day 2020 
• See here for BD’s global health site for tuberculosis
• Why is UNITAID investing in tuberculosis diagnostics
• FIND in the AMR Stakeholder Guide

Global markets | Why we need to think global to tackle AMR

Moderator:

• Marc Lemonnier – Founding CEO, Antabio SAS

Speakers:

• Heiman Wertheim – Head of Clinical Microbiology Department, Radboud University Medical Center
• Anand Anandkumar – CEO, Bugworks
• Alexandra Cameron – Senior Technical Manager Strategy Team, UNITAID
• Bruce Altevogt, Vice President and Head External Medical Engagement, Hospital Business Unit, Pfizer

Further reading tips:

• More information about the Open access global treatment guideline for antimicrobials, by Heiman Wertheim
• Wellcome Trust and Pfizer launch surveillance program to combat growing threat of antimicrobial resistance in sub-saharan africa 
• Unitaid is supporting the LONGEVITY project of University of Liverpool
• Unitaid deepens its commitment to fighting epidemics old and new, marks World Tuberculosis Day
• C-Camp has launched C-CAMP COVID-19 innovations deployment accelerator
• Life science incubator C-CAMP launches AMR accelerator programme to encourage antimicrobial resistance innovations,14 August 2020

Clinical trials | Why global networks are crucial to speed up late stage clinical development

Moderator:

• Ron de Winter – Programme Manager European Projects, UMC Utrecht

Speakers:

• Seamus O’Brien – R&D Director, GARDP
• Tim Jinks – Head of Antibiotic Resistance Infections Program, Wellcome Trust
• Florence Séjourné – CEO, DaVolterra & President, BEAM Alliance
• Kamini Walia – Head of AMR, ICMR, Government of India

Further reading tips:

• More information about European Clinical Research Alliance on Infectious Diseases
• COMBACTE: Combatting bacterial resistance in Europe 
• By Wellcome Trust: The growing crisis in antibiotic R&D: opportunities for G20 member action to support sustainable innovation & further information on WT’s activities to fight against AMR
• Enabling AMR-related Clinical Trials in India: Network Exploratory Workshop 
• Latest news by GARDP can be found here
• Webinar recording by GARDP: The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study 
• Wellcome and GARDP in the AMR Stakeholder Guide

Regulatory perspective | Current status and the post-COVID outlook for antibiotic clinical trials & approvals

Moderator:

• John Rex, Chief Medical Officer, F2G Ltd.

Speakers:

• Sumathi Nambiar – Director Division of Anti-Infective Products, Office of Infectious Diseases, FDA
• Marco Cavalieri – Head of Antiinfectives and Vaccines, Safety&Efficacy Sector, EMA

Further reading tips:

• Upcoming PACCARB Meeting: September 9-10, 2020 Virtual Public Meeting – Antimicrobial Resistance and COVID-19 
• Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea, public workshop by FDA, NIAID and CDC
• COVID-19: EMA sets up infrastructure for real-world monitoring of treatments and vaccines 
• Launch of public consultation on joint network strategy to 2025, 6 July

Start-up campus | Live pitches with jury voting hosted by Novo Repair Impact Fund

Congratulations to the winner of our Start-up up pitch session, Neciah Dorh, CEO & Co-Founder of FluoretiQ.

Jury Members:

• Peter Jackson, AMR Centre (Moderator)
• Camilla Petrycer Hansen, Novo Holding 
• Erin Duffy, Chief of R&D, CARB-X
• Holger Zimmermann, CEO, AiCuris
• Fiona Marston, Director, CEIDR 

With pitches from:

• Irene Wütherich , Co-Founder, Spherobiotics
• Thomas Hesterkamp, Head of Translational Project Management Office, HZI/DZIF & Myxobiotics
• Miron Tokarski, CEO & Co-Founder, Genomtec
• Neciah Dorh, CEO & Co-Founder, FluoretiQ

Further reading tips:

• News release, 18 August, AiCuris to launch AiCubator to fight AMR
• Novo REPAIR Impact Fund closed its most recent round on 31 Jul 2020. Go here for current details
• Latest investment news of CARB-X include Evotec, Spanish bioetech Vaxdyn and French Eligo Bioscience. Further news can be found here
• Please find an update on CEIDR’s activities here
• News release, AMR Centre, 26 June: Major boost in global fight against antimicrobial resistance as AMR Centre receives share of Strength in Places Fund award 
• AiCuris in the AMR Stakeholder Guide

SME campus (Part I) | Focus on therapeutics

Speakers:

• Marc Gitzinger – CEO and Founder, BioVersys AG
• Nadine Taudte – Head of Laboratory, Periotrap Pharmaceuticals
• Samareh Azeredo da Silveira Lajaunias – Founding Partner and General Manager, Combioxin SA
• Holger Zimmermann,  CEO, AiCuris

Further reading tips:

• More information on Periotrap’s activities can be found here
• Petriotrap’s antimicrobial activity study has been published in April this year showing biofilm inhibition of our developed drug formulation, now the according paper detailing its optimized mechanical and drug release properties is out as well
• News release, 14 July: BIOVERSYS AND PARTNERS FROM LILLE SIGN LONG-TERM COLLABORATION AGREEMENT CREATING A UNIQUE CROSS-BORDER AMR CLUSTER IN ANTIMICROBIAL RESEARCH EXCELLENCE 
• News release, 23 June: BIOVERSYS RECEIVES QIDP DESIGNATION FROM THE U.S. FDA FOR THE DEVELOPMENT OF A FIXED COMBINATION OF BVL-GSK098 AND ETH 
• News release, AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference 
• News release, 4 May: Combioxin SA announces that it has received positive feedback from FDA on its pre- investigational new drug application (PIND) for use of CAL02 in COVID-19 patients at high risk of secondary bacterial infections 
• BioVersys AG, Periotrap Pharmaceuticals, AiCuris in the AMR Stakeholder Guide

SME campus (Part II) | Focus on diagnostics

Moderation:

• Betsy Wonderly Trainor, Alliance Manager, CARB-X

Speakers:

• Colin Denver – CEO, SpeeDx
• Peter Haug – CFO & Co-Founder, Head of Business Development & Licensing, Noscendo GmbH
• Piotr Gastrecki – CTO, Scope Fluidics
• Rosemarie Preyer – GenID GmbH
• Doug Kwon, Scientific Co-founder, Day Zero Diagnostics & Associate Professor, Harvard Medical School

Further reading tips:

• News release, 16 June: SpeeDx and Roche Partner to Expand Access to Antibiotic Resistance Tests
• News release, 14 May, Noscendo GmbH: Faster pathogen identification with new method
• News release, 20 August: Scope Fluidics begins preparations for the accelerated registration procedure of the PCR|ONE SARS-CoV-2 panel in the USA
• News release on the AID SARS-CoV-2 Detection Kit that allows a Real time PCR screening kit for the fast and sensitive detection of SARS-CoV-2 RNA, starting from swab material from the throat or nasopharynx as well as bronchoalveolar lavage
• News release, 11 May: Day Zero Diagnostics Awarded $6.2 Million in CARB-X Funding for Development of New Technology to Rapidly Diagnose Superbug Infections and Determine the Most Effective Antibiotic for Treatment 
• CARB-X in the AMR Stakeholder Guide

Financing resistance | Why new investors are urgently needed and where they come from

Moderator:

• Peter Beyer – Senior Advisor Department of Essential Medicines & Health Products, WHO

Speakers:

• Thomas Cueni – Director General, IFPMA
• James Anderson – Head of Corporate Government Affairs, GSK
• Silas Holland – Head of External Affairs for the AMR Action Fund &  Director for Global Public Policy MSD
• Deborah A O’Neil – CEO, NovaBiotics Ltd & Board Member, BEAM Alliance
• Aleks Engel – Partner, Novo Holdings (Novo Seeds) & Director, REPAIR Impact Fund at Novo Holdings

Further reading tips:

• All background information about the AMR Action Fund can be found here
• BEAM Alliance will issue a new reflection paper on the AMR Action Fund TODAY. Please stay tuned and have a look here
• European Biotechnology News, 13 July: AMR: Big Pharma sets up US$1bn Fund 
• BEAM Alliance and REPAIR Impact Fund at Novo Holdings in the AMR Stakeholder Guide

Spotlight on UK | Investor Action on AMR

Watch the session recording here 

Sponsored by:

Moderator:

• Louise Norton-Smith, Head of Global Antimicrobial Resistance Strategy & Delivery, UK Department of Health & Social Care

Keynote:

• Dame Sally Davies – UK Special Envoy on Antimicrobial Resistance & former Chief Medical Officer for England

Speakers for the panel discussion:

• Maria Lettini, Executive Director, FAIRR Initiative
• Mara Lilley, Investor Engagement Manager, Access to Medicine Foundation
• Catherine McCabe, Senior Associate | Analyst | Responsible Investment, BMO Global Asset Management (EMEA)
• Matt Crossman, Stewardship Director, Rathbone Investment Management

Further reading tips:

• News release, 23 January, FAIRR Initiative
• More information about the “Investor Action on AMR” initiative can be found here
• Viewpoint, 20 August, by Abigail Herron, Aviva Investors: The role of investors in addressing AMR 
• UK Government and Access to Medicine Foundation in the AMR Stakeholder Guide

Behind the scenes | Perspectives from investors, accelerators & incubators

Moderator:

• Erin Duffy – Chief of Research & Development, CARB-X

Speakers:

• Aleks Engel – Partner, Novo Holdings (Novo Seeds) & Director, REPAIR Impact Fund at Novo Holdings
• Uzma Choudry – VC Investor at Octopus Ventures
• Igor Orshanskiy, Associate Director Business Development & Alliance Management, AiCuris
• Graham Somers, IMI portfolio Director, GSK

Further reading tips:

• All news released by CARB-X can be found here
• News release, AiCuris launches “PREP – Pandemic and Resistance Emergency Preparedness” program at upcoming 4th AMR Conference 
• All information about the IMI AMR Accelerator can be found here
• IMI AMR Accelerator – Data Call: Call for preclinical and clinical data sets from the study of prevention or treatment of bacterial infections 
• Further news from the IMI AMR Accelerator and its partners can be found here
• THE TIMES, article by Uzma Chaudry, 3 August: Change the vaccine model to prepare for the next pandemic 

Expert campus | Perspective on late stage clinical development

Moderation:

• Fiona Marston, Director, Centre of Excellence in Infectious Diseases (CEIDR)
  
  Speakers:
• Sarah Paulin, Technical Officer on Antimicrobial Resistance (AMR), World Health Organization (WHO)
• Laurenz Kellenberger – CSO, Basilea
• Patrick Velicitat – CMO, Allecra

Further reading tips:

• More about the WHO’s antibacterial pipeline reports can be found here
• News release, 11 August, Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19
• News release, 25 February: Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections 

Expert campus | Animal Health

Speakers:

• Klaus Hellmann – Klifovet AG
• Harald Peter – Fraunhofer IZI-BB
• Christophe Chatain – Executive assistant & Sales Manager, Vetophage
• Mai Huong Chatain-Ly -President & Scientific Director, Vetophage
• Hosny El-Adawy – Institute of Bacterial Infections and Zoonoses, Friedrich-Loeffler-Institut (FLI)

Further reading tips:

• Learn more about the European AVANT project, working on viable alternatives to Colistin and Zinc Oxide in the European Swine Industry 
• Learn more about services for the animal health industry at KLIVOFET AG
• Article, Journal of Global Antimicrobial Resistance, September 2020: In vitro and in vivo assessment of phage therapy against Staphylococcus aureuscausing bovine mastitis
• Learn more about the phage therapy approach in animal health by VetoPhage
• Article, 30 June 2020: Evaluation of phage therapy in the treatment of Staphylococcus aureus-induced mastitis in mice 
• Article by Fast Company, 26 August: American chickens covered in chlorine have become a hot-button Brexit issue in Britain 
• More information about the National Reference Laboratory for Bovine Genital Campylobacteriosis
• Learn more about the Point-of-need diagnosis of mastitis developed by the MANTRA Consortium with Fraunhofer IZI-BB and BiFlow Systems GmbH
• Article, 29 January, by Fraunhofer IZI-BB (in German only)
• Overview of Point-of-Care Technologies by Fraunhofer IZI-BB

Expert campus | Novel approaches in Drug development

Moderator:

• Till  Schäberle – Professor, Department of Insect Biotechnology at University of Gießen &  Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)

Speakers:

• Albina Poljak – Director Business Development, PhagoMed Biopharma GmbH
• Timothy Schulz-Utermoehl – Co-founder & Director, Pedanius Therapeutics
• Niamh Máire Mohan – Pre-Clinical Technologist, Nuritas limited
• Till  Schäberle – Professor, Department of Insect Biotechnology at University of Gießen &  Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)
• Cesar de la Fuente – Machine Biology Group, University of Pennsylvania

Further reading tips:

• News release, 16 July: Phagomed selected for EIT Gold Track program
• News release, 22 April: Nuritas Enters the Race to Find Therapeutic Peptides for the Treatment of COVID-19 
• Article, 23 August 2019 about a joint venture between Nuritas and Stonehaven Incubate: AI to accelerate animal health ingredient discovery
• Learn more about AI-driven research for antibiotic discovery at De la Fuente Lab, University of Pennsylvania 
• Learn more about the Department of Insect Biotechnology at University Gießen
• News release, 19 November 2019: A new antibiotic to combat drug-resistant bacteria
• Learn more about the RNAi-based approach of Pedanius Therapeutics to combat gram-negative bacterial infections

Closing session The future of AMR: How a new post-COVID-19 policy roadmap could look like

Watch the session recording here 

Moderator:

• Marc Gitzinger – CEO & Vice-President, BioVersys AG, BEAM Alliance

Speakers:

• Renu Swarup –  Secretary, Head of Department of Biotechnology (DBT), Ministry of Science and Technology,  Government of India
• Dame Sally Davies – UK Special Envoy on Antimicrobial Resistance & former Chief Medical Officer for England
• Tiemo Woelken – MEP S&D German, vice-chair of European Parliament MEP Interest Group on AMR
• Catharina Boehme – CEO, FIND
• Evan Loh, MD, CEO, Paratek & Chair, Antimicrobials Working Group, US

Further reading tips:

• BEAM Alliance and partners will release a call for action TODAY! Please stay tuned and have a look here
• More information on Antimicrobial Resistance activities of FIND
• Learn more about the Antimicrobials Working Group, US
• More information about the MEP Interest Group on Antimicrobial Resistance at European Public Health Alliance
• BEAM Alliance and FIND in the AMR Stakeholder Guide